微小RNA是结直肠癌耐药性的重要调节因子。
MicroRNAs are important regulators of drug resistance in colorectal cancer.
作者信息
Zhang Yang, Wang Jing
机构信息
.
出版信息
Biol Chem. 2017 Jul 26;398(8):929-938. doi: 10.1515/hsz-2016-0308.
Abstract
Despite of continuous development of cancer treatment over the past decades, drug resistance is still one of the major hurdles of effective therapy for advanced colorectal cancer (CRC) worldwide and the understanding of its underlying mechanisms remains limited. Data which have emerged suggests that many microRNAs (miRNAs) may contribute to drug resistance in CRC. Major findings on miRNA functions in drug resistance of CRC are systemically reviewed here, with the goal of providing new updates to broaden our comprehension of its mechanisms and evidence to utilize miRNAs as potential therapeutic targets for CRC treatment.
摘要
尽管在过去几十年中癌症治疗不断发展，但耐药性仍是全球晚期结直肠癌（CRC）有效治疗的主要障碍之一，对其潜在机制的了解仍然有限。已出现的数据表明，许多微小RNA（miRNA）可能与CRC的耐药性有关。本文系统综述了miRNA在CRC耐药中的主要功能研究结果，目的是提供新的进展，以拓宽我们对其机制的理解，并为将miRNA用作CRC治疗的潜在靶点提供依据。
相似文献
1
MicroRNAs are important regulators of drug resistance in colorectal cancer.微小RNA是结直肠癌耐药性的重要调节因子。
Biol Chem. 2017 Jul 26;398(8):929-938. doi: 10.1515/hsz-2016-0308.
2
MicroRNA as Regulators of Cancer Stem Cells and Chemoresistance in Colorectal Cancer.微小RNA作为结直肠癌中癌症干细胞和化疗耐药性的调节因子
Curr Cancer Drug Targets. 2016;16(9):738-754. doi: 10.2174/1568009616666151118114759.
3
MicroRNA: A new player in response to therapy for colorectal cancer.微小 RNA：结直肠癌治疗反应的新角色。
J Cell Physiol. 2019 Jun;234(6):8533-8540. doi: 10.1002/jcp.27806. Epub 2018 Nov 27.
4
MicroRNAs and colorectal cancer chemoresistance: New solution for old problem.微小 RNA 与结直肠癌化疗耐药：老问题的新解决方案。
Life Sci. 2020 Oct 15;259:118255. doi: 10.1016/j.lfs.2020.118255. Epub 2020 Aug 17.
5
MicroRNAs as Regulators, Biomarkers and Therapeutic Targets in the Drug Resistance of Colorectal Cancer.微小RNA作为结直肠癌耐药中的调节因子、生物标志物和治疗靶点
Cell Physiol Biochem. 2016;40(1-2):62-76. doi: 10.1159/000452525. Epub 2016 Nov 14.
6
The Role of Tumor Stem Cells in Colorectal Cancer Drug Resistance.肿瘤干细胞在结直肠癌药物耐药中的作用。
Cancer Control. 2024 Jan-Dec;31:10732748241274196. doi: 10.1177/10732748241274196.
7
MicroRNAs as potential therapeutic targets to predict responses to oxaliplatin in colorectal cancer: From basic evidence to therapeutic implication.微小 RNA 作为预测结直肠癌对奥沙利铂反应的潜在治疗靶点：从基础证据到治疗意义。
IUBMB Life. 2019 Oct;71(10):1428-1441. doi: 10.1002/iub.2108. Epub 2019 Jul 19.
8
MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer.微小RNA作为结直肠癌新的预测生物标志物和治疗靶点
World J Gastroenterol. 2014 Sep 7;20(33):11727-35. doi: 10.3748/wjg.v20.i33.11727.
9
The Roles of Cancer Stem Cells and Therapy Resistance in Colorectal Carcinoma.癌症干细胞与结直肠癌耐药的关系
Cells. 2020 Jun 3;9(6):1392. doi: 10.3390/cells9061392.
10
Overcoming stemness and chemoresistance in colorectal cancer through miR-195-5p-modulated inhibition of notch signaling.通过 miR-195-5p 调控抑制 Notch 信号通路克服结直肠癌细胞干性和化疗耐药性。
Int J Biol Macromol. 2018 Oct 1;117:445-453. doi: 10.1016/j.ijbiomac.2018.05.151. Epub 2018 May 28.
引用本文的文献
1
Mechanisms of drug resistance in hepatocellular carcinoma.肝细胞癌中的耐药机制。
Biol Proced Online. 2025 May 28;27(1):19. doi: 10.1186/s12575-025-00281-6.
2
Elucidating the Mechanisms of Acquired Palbociclib Resistance via Comprehensive Metabolomics Profiling.通过全面代谢组学分析阐明获得性帕博西尼耐药的机制
Curr Issues Mol Biol. 2025 Jan 2;47(1):24. doi: 10.3390/cimb47010024.
3
The expression of exosomal and cellular miRNAs in predicting oxaliplatin resistance in colorectal cancer cells: an in silico and in vitro study.外泌体和细胞微小RNA在预测大肠癌细胞对奥沙利铂耐药性中的表达：一项计算机模拟和体外研究
BMC Cancer. 2025 Jan 9;25(1):46. doi: 10.1186/s12885-024-13392-2.
4
Modulatory effects of miRNAs in doxorubicin resistance: A mechanistic view.miRNAs 在多柔比星耐药中的调控作用：一种机制观点。
Funct Integr Genomics. 2024 Sep 2;24(5):150. doi: 10.1007/s10142-024-01431-x.
5
The Role of Tumor Stem Cells in Colorectal Cancer Drug Resistance.肿瘤干细胞在结直肠癌药物耐药中的作用。
Cancer Control. 2024 Jan-Dec;31:10732748241274196. doi: 10.1177/10732748241274196.
6
Thymoquinone Increases the Sensitivity of SW-480 Colon Cancer Cells to 5-Fluorouracil.百里醌增加SW-480结肠癌细胞对5-氟尿嘧啶的敏感性。
Biomed Res Int. 2024 Jul 9;2024:6231095. doi: 10.1155/2024/6231095. eCollection 2024.
7
Review of 5-FU resistance mechanisms in colorectal cancer: clinical significance of attenuated on-target effects.结直肠癌中5-氟尿嘧啶耐药机制综述：减弱的靶向效应的临床意义
Cancer Drug Resist. 2023 Apr 29;6(2):257-272. doi: 10.20517/cdr.2022.136. eCollection 2023.
8
MicroRNA-425: A Pivotal Regulator Participating in Tumorigenesis of Human Cancers.MicroRNA-425：参与人类癌症发生的关键调节因子。
Mol Biotechnol. 2024 Jul;66(7):1537-1551. doi: 10.1007/s12033-023-00756-5. Epub 2023 Jun 19.
9
HIF-1-Induced hsa-miR-429: Understanding Its Direct Targets as the Key to Developing Cancer Diagnostics and Therapies.缺氧诱导因子-1诱导的人源微小RNA-429：了解其直接靶点是开发癌症诊断和治疗方法的关键。
Cancers (Basel). 2023 May 25;15(11):2903. doi: 10.3390/cancers15112903.
10
Mir-153-3p Modulates the Breast Cancer Cells' Chemosensitivity to Doxorubicin by Targeting KIF20A.Mir-153-3p 通过靶向 KIF20A 调节乳腺癌细胞对阿霉素的化学敏感性。
Cancers (Basel). 2023 Mar 11;15(6):1724. doi: 10.3390/cancers15061724.
本文引用的文献
1
microRNA Therapeutics in Cancer - An Emerging Concept.微小 RNA 治疗癌症——一个新兴概念。
EBioMedicine. 2016 Oct;12:34-42. doi: 10.1016/j.ebiom.2016.09.017. Epub 2016 Sep 20.
2
Targeting the metabolic pathway of human colon cancer overcomes resistance to TRAIL-induced apoptosis.靶向人类结肠癌的代谢途径可克服 TRAIL 诱导的细胞凋亡抵抗。
Cell Death Discov. 2016 Sep 12;2:16067. doi: 10.1038/cddiscovery.2016.67. eCollection 2016.
3
Targeting FLT3-ITD signaling mediates ceramide-dependent mitophagy and attenuates drug resistance in AML.靶向FLT3-ITD信号传导介导神经酰胺依赖性线粒体自噬并减弱急性髓系白血病中的耐药性。
Blood. 2016 Oct 13;128(15):1944-1958. doi: 10.1182/blood-2016-04-708750. Epub 2016 Aug 18.
4
Transforming Growth Factor β Mediates Drug Resistance by Regulating the Expression of Pyruvate Dehydrogenase Kinase 4 in Colorectal Cancer.转化生长因子β通过调节丙酮酸脱氢酶激酶4的表达介导结直肠癌的耐药性。
J Biol Chem. 2016 Aug 12;291(33):17405-16. doi: 10.1074/jbc.M116.713735. Epub 2016 Jun 21.
5
miR-139-5p Inhibits the Epithelial-Mesenchymal Transition and Enhances the Chemotherapeutic Sensitivity of Colorectal Cancer Cells by Downregulating BCL2.miR-139-5p通过下调BCL2抑制上皮-间质转化并增强结肠癌细胞的化疗敏感性。
Sci Rep. 2016 May 31;6:27157. doi: 10.1038/srep27157.
6
miR-143 or miR-145 overexpression increases cetuximab-mediated antibody-dependent cellular cytotoxicity in human colon cancer cells.miR-143或miR-145的过表达增强了西妥昔单抗介导的人结肠癌细胞的抗体依赖性细胞毒性。
Oncotarget. 2016 Feb 23;7(8):9368-87. doi: 10.18632/oncotarget.7010.
7
Pharmacologic resistance in colorectal cancer: a review.结直肠癌中的药理学耐药性：综述
Ther Adv Med Oncol. 2016 Jan;8(1):57-84. doi: 10.1177/1758834015614530.
8
Cancer Metabolism and Drug Resistance.癌症代谢与耐药性
Metabolites. 2015 Sep 30;5(4):571-600. doi: 10.3390/metabo5040571.
9
Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer.利用一种新型的miR-519c-HuR-ABCG2调控途径克服结直肠癌的化疗耐药性。
Exp Cell Res. 2015 Nov 1;338(2):222-31. doi: 10.1016/j.yexcr.2015.09.011. Epub 2015 Sep 18.
10
MicroRNA-587 antagonizes 5-FU-induced apoptosis and confers drug resistance by regulating PPP2R1B expression in colorectal cancer.微小RNA-587通过调节结直肠癌中PPP2R1B的表达来拮抗5-氟尿嘧啶诱导的细胞凋亡并赋予耐药性。
Cell Death Dis. 2015 Aug 6;6(8):e1845. doi: 10.1038/cddis.2015.200.
Zotero 插件